Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.

Wallace J BrownleeChristian WolfHans-Peter HartungTheo DingermannNadia AnshasiRichard Ac ClarkMaria TrojanoKrzysztof SelmajBernard Mj UitdehaagCarmen TurJens WuerfelGabriele DallmannJulian WitteMartina SintzelOlga BobrovnikovaJeffrey A Cohen

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)

Published data support the use of FO-DMTs in MS. The consensus may aid shared decision-making. While our consensus focused on Europe, the results may contribute to enhanced quality standards for FO-DMTs use elsewhere.

Keyphrases

multiple sclerosis
clinical practice
mass spectrometry
electronic health record
ms ms
white matter
randomized controlled trial
big data
quality improvement
data analysis